title: High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases.
abstract: In order to reduce systemic side effects and increase intrahepatic mitomycin C (MMC) concentrations, isolated hyperthermic liver perfusion (IHLP) has been performed using MMC. This article describes the pharmacokinetics of MMC in IHLP and presents our clinical experience with its use in six patients suffering from unresectable liver metastases. Primary tumors consisted of colorectal carcinomas in three cases, breast cancer in two, and a choroidal melanoma in one. Dosages of MMC varied between 0.5 and 1.0 mg MMC/kg body weight. MMC was added as a bolus directly into the extracorporeal circuit. Intrahepatic temperature was elevated to 40.0-41.0 degrees C by hyperthermic perfusion. MMC concentrations were measured in peripheral blood (preperfusion, then at 5, 30, and 55 min during perfusion, and finally at 5 and 60 min and 6 and 24 h after perfusion) and in recirculating perfusate (5, 30, and 55 min). While markedly elevated MMC concentrations (maximum 6290 ng/mL) were found in the liver perfusate, systemic concentrations remained low (maximum 45 ng/mL), indicating no considerable leakage. MMC concentrations in the perfusate constantly decreased during perfusion. After rinsing with 1500 mL saline, a mean concentration of 52.5+/-33 ng MMC/mL was measured in the washout from 5 patients. In 1 patient with a colorectal carcinoma, MMC concentrations in the perfusion medium were 10-fold and in the plasma 2-fold higher than in the other patients. This high MMC concentration caused severe intrahepatic vascular damage and finally led to the patient's death. In conclusion, IHLP and intrahepatic perfusion with MMC resulted in a high response of hepatic tumors. Systemic exposure of MMC can be reduced effectively by isolated perfusion. However, hepatic toxicity of MMC must be considered.
authors.affiliation: Department of Abdominal and Transplantation Surgery, Hannover Medical School, Germany.
authors.forename: K J
authors.initials: KJ
authors.lastname: Oldhafer
authors.forename: M K
authors.initials: MK
authors.lastname: Frerker
authors.forename: H
authors.initials: H
authors.lastname: Lang
authors.forename: J
authors.initials: J
authors.lastname: Fauler
authors.forename: P
authors.initials: P
authors.lastname: Flemming
authors.forename: E
authors.initials: E
authors.lastname: Schmoll
authors.forename: S
authors.initials: S
authors.lastname: Nadalin
authors.forename: L
authors.initials: L
authors.lastname: Moreno
authors.forename: R
authors.initials: R
authors.lastname: Pichlmayr
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001943:Breast Neoplasms / Q000628:therapy; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002830:Choroid Neoplasms / Q000628:therapy; D015179:Colorectal Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin; D001219:Aspartate Aminotransferases